Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease

Journal of Clinical Oncology

Volumn 14, Issue 2, 1996, Pages 572-578

  Gajewski, J L ^a   Phillips, G L ^a   Sobocinski, K A ^a   Armitage, J O ^a   Gale, R P ^a   Champlin, R E ^a   Herzig, R H ^a   Hurd, D D ^a   Jagannath, S ^a   Klein, J P ^a   Lazarus, H M ^a   McCarthy Jr , P L ^a   Pavlovsky, S ^a   Peterson, F B ^a   Rowlings, P A ^a   Russell, J A ^a   Silver, S M ^a   Vose, J M ^a   Wiernik, P H ^a   Bortin, M M ^a   Horowitz, M M ^a   more..

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION COMPLICATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SCHOOL CHILD; TREATMENT FAILURE;

EID: 9044237273     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.2.572     Document Type: Article

References (45)

1. Urba WJ, Longo DL: Medical progress. Hodgkin's disease. N Engl J Med 326:678-687, 1992
2. Bonadonna G, Valagussa P, Santoro A: Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. Ann Intern Med 104:739-746, 1986
3. Klimo P, Connors JM: An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program. Semin Hematol 25:34-40, 1988
4. Crnkovich MJ, Leopold K, Hoppe RJ, et al: Stage I to IIB Hodgkin's disease the combined experience at Stanford University and the Joint Center for Radiation Therapy. J Clin Oncol 5:1041-1049, 1987
5. Piga A, Ambrosetti A, Todeschini G, et al: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease. Cancer Treat Rep 68:947-951, 1984
6. Hagemeister FB, Tannir N, McLaughlin P, et al: MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol 5:556-561, 1987
7. Cheson BD, Lacerna L, Leyland-Jones B, et al: Review. Autologous bone marrow transplantation. Current status and future directions. Ann Intern Med 110:51-65, 1989
8. Armitage JO: Bone marrow transplantation. N Engl J Med 330:827-838, 1994
9. Mascret B, Maraninchi D, Gastaut JA, et al: Treatment of malignant lymphoma with high dose of chemo or chemoradiotherapy and bone marrow transplantation. Eur J Cancer Clin Oncol 22:461-471, 1986
10. Anderson JE, Litzow MR, Appelbaum FR, et al: Allogeneic, syngeneic, and autologous bone marrow transplantation for Hodgkin's disease: The 21-year Seattle experience. J Clin Oncol 11:2342-2361, 1993
11. Jagannath S, Armitage JO, Dicke KA, et al: Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 7:179-185, 1989
12. Reece DE, Barnett MJ, Connors JM, et al: Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 9:1871-1879, 1991
13. Gribben JG, Linch DC, Singer CRJ, et al: Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 73:340-344, 1989
14. Wheeler C, Antin JH, Churchill WH, et al: Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: A dose-finding study. J Clin Oncol 8:648-656, 1990
15. Zulian GB, Selby P, Milan S, et al: High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease. Br J Cancer 59:631-635, 1989
16. Ahmed T, Ciavarella D, Feldman E, et al: High-dose, potentially myeloablative chemotherapy and autologous bone marrow transplantation for patients with advanced Hodgkin's disease. Leukemia 3:19-22, 1989
17. Armitage JO, Bierman PJ, Vose JM, et al: Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. Am J Med 91:605-611, 1991
18. Carella AM, Congiu AM, Gaozza E, et al: High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: An Italian Study Group report. J Clin Oncol 6:1411-1416, 1988
19. Philip T, Dumont J, Teillet F, et al: High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease. Br J Cancer 53:737-742, 1986
20. Yahalom J, Gulati S: Autologous bone marrow transplantation for refractory or relapsed Hodgkin's disease: The Memorial Sloan-Kettering Cancer Center experience using high-dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiation. Ann Oncol 2:67-71, 1991
21. Gingrich RD, Ginder GD, Burns LJ, et al: BVAC ablative chemotherapy followed by autologous bone marrow transplantation for patients with advanced lymphoma. Blood 75:2276-2281, 1990
22. Rapoport AP, Rowe JM, Kouides PA, et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pretransplant disease status for predicting outcome. J Clin Oncol 11:2351-2361, 1993
23. Körbling M, Holle R, Haas R, et al: Autologous blood stem-cell transplantation in patients with advanced Hodgkin's disease and prior radiation to the pelvic site. J Clin Oncol 8:978-985, 1990
24. Chao NS, Nademanee AP, Long GD, et al: Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin's disease. J Clin Oncol 9:1575-1579, 1991
25. Thomas ED: Karnofsky Memorial Lecture. Marrow transplantation for malignant disease. J Clin Oncol 1:517-531, 1985
26. Jones RJ, Ambinder RF, Piantadosi S, et al: Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649-653, 1991
27. Appelbaum FR, Sullivan KM, Thomas ED, et al: Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease. J Clin Oncol 3:1490-1494, 1985
28. Phillips GL, Reece DE, Barnett MJ, et al: Allogeneic marrow transplantation for refractory Hodgkin's disease. J Clin Oncol 7:1039-1045, 1989
29. Jones RJ, Piantadosi S, Mann RB, et al: High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 8:527-537, 1990
30. Phillips GL, Herzig RH, Lazarus HM, et al: High-dose chemotherapy, fractionated total-body irradiation and allogeneic marrow transplantation for malignant lymphoma. J Clin Oncol 4:480-488, 1986
31. Champlin RE, Horowitz MM, van Bekkum DW, et al: Graft failure following bone marrow transplantation for severe aplastic anemia: Risk factors and treatment results. Blood 73:606-613, 1989
32. Gale RP, Bortin MM, van Bekkum DW, et al: Risk factors for acute graft-vs-host disease. Br J Haematol 67:397-406, 1987
33. Atkinson K, Horowitz MM, Gale RP, et al: Risk factors for chronic graft-versus-host disease after HLA-identical sibling marrow transplantation. Blood 75:2459-2464, 1990
34. Borgan Ø, Liestøl K: A note on confidence intervals and bands for the survival curve based on transformations. Scand J Stat 17:35-41, 1990
35. Fleming TR, Harrington DP: Counting Processes and Survival Analyses. New York, NY, Wiley, 1991
36. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
37. Bearman SI, Appelbaum FR, Back A, et al: Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 7:1288-1294, 1989
38. Kessinger A, Bierman PJ, Vose JM, et al: High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. Blood 77:2322-2325, 1991
39. Williams SF, Bitran JD, Richards JM, et al: Peripheral blood-derived stem cell collections for use in autologous transplantation after high dose chemotherapy: An alternative approach. Bone Marrow Transplant 5:129-133, 1990
40. Socinski MA, Cannistra SA, Elias A, et al: Granulocyte-macrophage colony stimulating factor expands the circulating haematopoietic progenitor cell compartment in man. Lancet 1:1194-1198, 1988
41. Haas R, Ho AD, Bredthauer U, et al: Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 18:94-98, 1990
42. To LB, Shepperd KM, Haylock DN, et al: Single high doses of cyclophosphamide enable the collection of high numbers of hematopoietic stem cells from the peripheral blood. Exp Hematol 18:442-447, 1990
43. Lasky LC, Hurd DD, Smith JA, et al: Peripheral blood stem cell collection and use in Hodgkin's disease. Comparison with marrow in autologous transplantation. Transfusion 29:323-327, 1989
44. Horowitz MM, Gale RP, Sondel PM, et al: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555-562, 1990
45. Rowlings PA, Horowitz MM, Armitage JO, et al: Report from the International Bone Marrow Transplant Registry and the North American Autologous Bone Marrow Transplant Registry, in Terasaki PI, Cecka JM (eds): Clinical Transplants 1993. Los Angeles, CA, UCLA Tissue Typing Laboratory, 1994, pp 101-108